General
Preferred name
GENISTEIN
Synonyms
Genestein ()
NPI 031L ()
BIO-300 ()
Genistein (NPI 031L) ()
Genistein-d4 ()
.alpha.-isosparteine ()
Bonistein ()
.alpha.-isospartein ()
.alpha.-sparteine ()
Sophoricol ()
4',5,7-trihydroxyisoflavone ()
Genisteine-alkaloid ()
NSC-36586 ()
.alpha.-isosparteine, (-)- ()
SIPI-807-1 ()
FW-635I-2 ()
NPI-031L ()
(-)-.alpha.-isosparteine ()
Isosparteine, alpha- ()
11-isosparteine ()
NSC-366737 ()
BIO 300 ()
Sparteine l-.alpha.-isosparteine ()
P&D ID
PD002146
CAS
446-72-0
187960-08-3
Tags
natural product
drug candidate
nuisance
available
Drug indication
Prostate cancer
Menopause symptom
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
Genistein may inhibit cancer cell growth by blocking enzymes required for cell growth. ; ; Genistein may decrease cardiovascular risk in postmenopausal women by interacting with the nuclear estrogen receptors to alter the transcription of cell specific genes. In randomized clinical trials, genistein was seen to increase the ratio of nitric oxide to endothelin and improved flow-mediated endothelium dependent vasodilation in healthy postmenopausal women [A14417]. In addition, genistein may have beneficial effects on glucose metabolism by inhibiting islet tyrosine kinase activity as well as insulin release dependent on glucose and sulfonylurea [A14417].
DESCRIPTION
Non-selective PI 3-kinase inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
EGFR kinase inhibitor. Also estrogen and PPARgamma ligand
(Tocriscreen Plus)
DESCRIPTION
Cytotoxic inhibitor of tyrosine kinase and topoisomerase II kinase
(LOPAC library)
DESCRIPTION
EGFR kinase inhibitor. Also estrogen and PPARĪ³ ligand
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
71
Organisms
7
Compound Sets
26
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
IPPI - DB
LOPAC library
MedChem Express Bioactive Compound Library
NPC Screening Collection
Nuisance compounds in cellular assays
NURSA ligand set
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
54
Molecular Weight
270.05
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
3
cLogP
2.58
TPSA
90.9
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.63
Structural alerts
1
Nonspecific/NOS
Flavonoid
Nuisance compounds in cellular assays
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzyme-Linked Receptors
Selectivity
Tyrosine kinase
Pathway
Angiogenesis
JAK/STAT Signaling
Tyrosine Kinase/Adaptors
Apoptosis
Autophagy
Metabolic Enzyme/Protease
Protein Tyrosine Kinase/RTK
Target
EGFR
CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5
Endogenous Metabolite
EGFR,Topoisomerase
MOA
Inhibitor
tyrosine kinase inhibitor
Source data
